Phase IIa Study of the Efficacy of ORM-12471 for Prevention of Cold-induced Vasospasm: a Randomised, Double-blind, Placebo-controlled, Single Centre Crossover Study in Patients With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Latest Information Update: 19 Feb 2022
At a glance
- Drugs ORM 12741 (Primary)
- Indications Raynaud's disease
- Focus Therapeutic Use
- Acronyms REINO
- Sponsors Orion Pharma
Most Recent Events
- 27 Oct 2014 New trial record